$MO

ALTRIA GROUP, INC. (MO): Results of Operations and Financial Condition

ALTRIA GROUP, INC. (MO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Altria Reports 2026 Second-Quarter and First-Half Results; Narrows 2026 Full-Year Earnings Guidance RICHMOND, Va. - July 30, 2026 - Altria Group, Inc. (NYSE: MO) today reports our 2026 second-quarter and first-half business results and narrows guidance for 2026 full-

Original reporting
Published Jul 30, 2026, 11:06 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 11:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$MO
Bullish
medium confidence
Mentioned
$MO
Relevance
8/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MOBullishMed
01

Why it matters

The key tradable update is the narrowed and raised full-year adjusted diluted EPS range, alongside quarterly EPS and revenue drivers, plus capital expenditure guidance and share repurchase/dividend cash returns.

02

Market read

Traders can reprice MO based on the updated EPS range and the disclosed drivers, especially the balance of second-half benefits and the capex increase.

03

What to watch

Investors should scrutinize the guidance assumptions: NJOY ACE not returning in 2026, moderated e-vapor growth impacts, and higher 2026 capex tied to USSTC facilities consolidation, which could pressure free cash flow.

Relevance 8/10Novelty 7/10Timing: pre-market today, guidance and quarterly results released via 8-K
alphai · Earnings readMO · 2026 second quarter and first half · ended June 30, 2026

Altria Reports 2026 Second-Quarter and First-Half Results; Narrows 2026 Full-Year Earnings Guidance

Solid half-year

Second-quarter adjusted diluted EPS increased 2.8% and first-half adjusted diluted EPS increased 4.9%, while the company raised the lower end of its full-year adjusted diluted EPS range. Revenue growth remained modest and oral tobacco products revenue declined.

Revenue
$11,539 million
1.6% y/y
EPS · non-GAAP
$2.80
4.9 % y/y

Key metrics

as reported
MetricValueq/qy/y
Q2 net revenuesGAAP$6,111 million0.1%
Q2 revenues net of excise taxesGAAP$5,356 million1.2%
Q2 reported effective tax rateGAAP21.5%(2.2) pp
Q2 adjusted effective tax ratenon-GAAP23.0%(0.3) pp
Q2 reported diluted EPSGAAP$1.37(2.8) %
Q2 adjusted diluted EPSnon-GAAP$1.482.8 %
First Half net revenuesGAAP$11,539 million1.6%
First Half revenues net of excise taxesGAAP$10,114 million3.1%
First Half reported effective tax rateGAAP22.6%(5.4) pp
First Half adjusted effective tax ratenon-GAAP23.0%(0.4) pp
First Half reported diluted EPSGAAP$2.6730.9 %
First Half adjusted diluted EPSnon-GAAP$2.804.9 %
Q2 asset impairment, exit and implementation costsGAAP$88 million (or $0.04 per share)
First Half asset impairment, exit and implementation costsGAAP$94 million (or $0.04 per share)
Q2 tobacco and health and certain other litigation itemsGAAP$95 million (or $0.05 per share)
First Half tobacco and health and certain other litigation itemsGAAP$97 million (or $0.04 per share)
First Half amortization of intangiblesGAAP$46 million (or $0.03 per share)
Q2 ABI-related special itemsGAAP$77 million (or $0.04 per share)
First Half ABI-related special itemsGAAP$78 million (or $0.04 per share)
Q2 income tax itemsGAAP$42 million (or $0.03 per share)
First Half income tax itemsGAAP$30 million (or $0.02 per share)

2026 full-year outlook

  • NoteAdjusted diluted EPS of $5.61 to $5.72
  • NoteAdjusted diluted EPS growth rate of 3.5% to 5.5% from a base of $5.42 in 2025
  • Note2026 capital expenditures of between $375 million and $450 million
  • NoteExpectation for a greater benefit from cigarette import and export activity in the second half of the year than in the first half
  • NoteExpectation that the second-half benefit from cigarette import and export activity will be more balanced between the third and fourth quarters
  • NoteNJOY ACE does not return to the marketplace in 2026

Capital returns

  • In the second quarter, we repurchased 0.8 million shares at an average price of $65.11 per share, for a total cost of $55 million.
  • Through the first half, we repurchased 5.3 million shares at an average price of $62.78 per share, for a total cost of $335 million.
  • As of June 30, 2026, we had $665 million remaining under our $2 billion share repurchase program, which expires on December 31, 2026.
  • We paid dividends of $1.8 billion and $3.6 billion in the second quarter and first half, respectively.

What drove it

  • Q2 net revenues were essentially unchanged as higher net revenues in the smokeable products segment and all other category, which included 2025 acquisition-related items, were offset by lower net revenues in the oral tobacco products segment.
  • First-half net revenue growth was primarily driven by higher net revenues in the smokeable products segment.
  • Q2 adjusted diluted EPS increased primarily due to higher adjusted OCI and fewer shares outstanding.
  • First-half adjusted diluted EPS increased primarily due to higher adjusted OCI and fewer shares outstanding.
  • Smokeable products Q2 net revenues increased 0.7%, primarily driven by higher pricing, partially offset by higher promotional investments, lower shipment volume and a higher percentage of discount shipment volume relative to premium versus the prior year.
  • Helix resumed shipments of 12-milligram on! PLUS in Florida, North Carolina and Texas in Mint, Wintergreen and Tobacco, with a national expansion planned for the third quarter.
  • Helix plans additional on! PLUS flavors across 6-, 9- and 12-milligram nicotine strengths, beginning with Blueberry Mint and Mango Pineapple, in the fourth quarter.

Concerns

  • The company cited moderated e-vapor industry growth on combustible and e-vapor product volumes.
  • The company cited increased macroeconomic uncertainty facing adult nicotine consumers.
  • Q2 oral tobacco products segment net revenues were lower.
  • Smokeable products faced lower shipment volume, higher promotional investments and an unfavorable volume mix change.
  • Q2 reported diluted EPS decreased 2.8%, primarily due to lower OCI, including higher tobacco and health and certain other litigation items, 2026 costs related to the USSTC Facilities Consolidation and unfavorable ABI-related special items.
  • The increase in capital expenditure guidance primarily reflects investments to support the USSTC Facilities Consolidation.

What to watch

  • National expansion of 12-milligram on! PLUS in the third quarter.
  • Additional on! PLUS flavor launches beginning in the fourth quarter.
  • The expected second-half benefit from cigarette import and export activity.
  • Execution of the USSTC Facilities Consolidation and capital expenditures of between $375 million and $450 million.
  • The company's expectation that NJOY ACE does not return to the marketplace in 2026.

Analysis

Altria reported modest top-line growth in the second quarter, with net revenues essentially unchanged at $6,111 million and revenues net of excise taxes up 1.2% to $5,356 million. First-half net revenues increased 1.6% to $11,539 million, while revenues net of excise taxes increased 3.1% to $10,114 million. The first-half increase was primarily driven by higher smokeable products segment net revenues, while second-quarter oral tobacco products segment net revenues declined.

Profit performance was stronger on an adjusted basis than on a reported basis. Q2 adjusted diluted EPS increased 2.8% to $1.48, driven primarily by higher adjusted OCI and fewer shares outstanding. Q2 reported diluted EPS declined 2.8% to $1.37, reflecting lower OCI, including higher litigation items, USSTC Facilities Consolidation costs and unfavorable ABI-related special items. First-half reported diluted EPS increased 30.9% to $2.67, primarily because the prior year included a non-cash impairment of the e-vapor reporting unit goodwill, while adjusted diluted EPS increased 4.9% to $2.80.

In smokeable products, higher pricing and higher refunds of taxes and duties supported reported OCI. Higher promotional investments, lower shipment volume and a higher proportion of discount shipment volume relative to premium were offsets to net revenue performance. The company also identified moderated e-vapor industry growth, macroeconomic uncertainty facing adult nicotine consumers, investments in contract manufacturing capabilities and planned reinvestment of Initiative cost savings as factors contemplated in its outlook.

Capital returns remained substantial, with $55 million of second-quarter share repurchases and $1.8 billion of dividends paid in the quarter. Through the first half, the company repurchased 5.3 million shares for $335 million and paid $3.6 billion in dividends. The company had $665 million remaining under its $2 billion repurchase program as of June 30, 2026.

Management narrowed full-year adjusted diluted EPS guidance to $5.61 to $5.72 and raised the lower end of the range. It expects a greater contribution from cigarette import and export activity in the second half than in the first half, with the benefit more balanced between the third and fourth quarters due to the timing of second-quarter benefits. Capital expenditure guidance increased to between $375 million and $450 million, primarily for the USSTC Facilities Consolidation.

Management, verbatim

In the second quarter, our operating companies continued to deliver against the priorities we outlined at the start of the year – advancing our smoke-free portfolio, strengthening our traditional tobacco businesses and delivering significant returns to shareholders,

Sal Mancuso, Altria’s Chief Executive Officer

We delivered strong first-half results, driving adjusted diluted EPS growth of 4.9%, and returned nearly $3.9 billion to shareholders through dividends and share repurchases combined.

Sal Mancuso, Altria’s Chief Executive Officer

We are raising the lower-end of our full-year 2026 guidance. We now expect to deliver adjusted diluted EPS in a range of $5.61 to $5.72, representing a growth rate of 3.5% to 5.5% from a base of $5.42 in 2025.

Sal Mancuso, Altria’s Chief Executive Officer

Not in the filing

stated, not guessed
  • Segment revenue amounts for smokeable products, oral tobacco products and all other category were not included in the supplied filing text.
  • Segment revenue comparisons for oral tobacco products and all other category were not included in the supplied filing text.
  • Gross profit and gross margin were not reported in the supplied filing text.
  • Operating income, operating margin and adjusted operating income were not reported in the supplied filing text.
  • Net income was not reported in the supplied filing text.
  • Operating cash flow and free cash flow were not reported in the supplied filing text.
  • Cash, cash equivalents, total debt and net debt were not reported in the supplied filing text.
  • Quarterly dividend per share was not reported in the supplied filing text.
  • A prior outlook document was not provided, so no actual-versus-prior-guidance comparison is available.
  • Revenue, gross margin, operating expense and tax-rate guidance were not provided.
  • The supplied filing text is truncated during the smokeable products section, so additional segment and financial metrics may not be present.

AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

This is Altria’s SEC 8-K with an earnings press release covering Q2 2026, first-half 2026, and updated full-year 2026 adjusted diluted EPS guidance.

Company-level read

Ticker impact

$MOBullishMedium confidence
Context

Altria reported Q2 and first-half results and narrowed 2026 adjusted diluted EPS guidance to $5.61 to $5.72.

Expected impact

Moderately positive bias for MO around the release, with follow-through dependent on whether investors view the guidance raise as durable versus dependent on second-half cigarette import/export benefits.

Evidence & confidence

The filing discloses a specific EPS range change and ties it to identifiable drivers (smoke-free expansion, moderated e-vapor growth, and second-half import/export benefit timing).

Market effects

Tobacco peers may see read-across on smoke-free execution (Helix on! PLUS expansion) and how much guidance depends on combustible volume offsets.

Limited direct regional spillover; primarily US consumer and regulatory/tax sensitivity.

Low; the disclosed drivers are largely US-focused (Helix expansion, USSTC manufacturing consolidation, NJOY ACE timing).

Counterpoint

The guidance raise may be more about timing and mix (second-half import/export benefits, cost timing) than underlying demand strength, leaving downside if volumes or e-vapor moderation diverge.

Key entities

  • Altria Group, Inc.

    Reported Q2 and first-half 2026 results and narrowed 2026 adjusted diluted EPS guidance to $5.61 to $5.72.

  • Helix

    Smoke-free unit expanding on! PLUS to 120,000 stores and planning additional flavors across nicotine strengths.

  • USSTC Facilities Consolidation

    Manufacturing consolidation plan driving higher 2026 capex expectations.

Every MO earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$MOMed

Yielding Dividend Stock That's Beating the Market in 2026

Altria Group (MO) reported 24% total returns in 2026, outpacing the S&P 500's 14%. Shares fell after Q2 earnings missed estimates, with revenue at $5.35B and EPS at $1.37. The company faces long-term risks due to declining cigarette use and competition in smokeless products. Altria trades at 12x forward earnings with a 6.4% yield, but its strategy to sustain growth remains uncertain.

$MOMed

Altria Units Sue FDA Over PMTA Rule, Spotlighting Review Delays

Altria Group (MO) subsidiaries Helix Innovations and NJOY sued the FDA over its 2021 PMTA rule, arguing it violates the Tobacco Control Act's 180-day review deadline. The lawsuit claims FDA delays begin with Acceptance and Filing Reviews. FDA has reduced its backlog but Altria seeks a court order to vacate the rule. MO stock traded between $54.70 and $77.06 over the past year, closing at $69.56 on Wednesday.

$MOMed

What's Going On With Altria Stock Monday? - Philip Morris Intl (NYSE:PM), Altria Group (NYSE:MO)

Altria Group (MO) stock rose after announcing a contract manufacturing deal with Philip Morris International (PM) affiliates to improve efficiency in tobacco operations. Initial shipments are expected in early 2027. The agreement supports Altria's 2028 goals but is not expected to impact 2026 financial results. MO traded at $67.84, with mixed technical indicators and a Hold consensus rating. PM shares also rose. According to Benzinga Pro, MO was up 3.87% and PM was up 2.60% at the time of public